Lupin announced a licensing agreement in Canada, aimed at strengthening its specialty pharma portfolio in regulated markets. The move supports the firm’s strategy to expand presence in high-value geographies.
Analysts believe the partnership could support medium-term revenue visibility from North America. Investors will watch product approvals and launch timelines for further cues.
